Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio beyond cystic fibrosis. The company is ramping up CASGEVY gene-editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results